Vanguard Reports 0 Shares in Core Laboratories
The Vanguard Group filed Amendment No. 4 to its Schedule 13G/A reporting 0 shares of Core Laboratories Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 4 to its Schedule 13G/A reporting 0 shares of Core Laboratories Inc. common stock. The filing states Vanguard's subsidiaries underwent an internal realignment on January 12, 2026, after which certain subsidiaries report beneficial ownership separately. The amendment shows Amount beneficially owned: 0 and Percent of class: 0%. The filing is signed by Ashley Grim as Head of Global Fund Administration on 03/26/2026.
Insights
Vanguard disaggregated holdings; this amendment reports no beneficial ownership in CLB.
The amendment records 0 shares beneficially owned and 0% of the class, reflecting reporting changes after an internal realignment on January 12, 2026. The text explains subsidiaries now report separately pursuant to SEC Release No. 34-39538.
Cash‑flow treatment and any trading activity are not disclosed in the excerpt; subsequent filings would show changes in holdings if they occur.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Schedule 13G/A amendment say about Vanguard's holdings in CLB?
Why does Vanguard report separate holdings after January 12, 2026?
Who signed the filing and when was it signed?
Is any other person's interest in the reported securities more than 5%?
AI-generated analysis. How Rhea-AI works. Not financial advice.